Lithium and Breastfeeding
Breastfeeding while taking lithium is generally not recommended according to FDA labeling, which states "nursing should not be undertaken during lithium therapy except in rare and unusual circumstances," but emerging evidence suggests it may be acceptable for healthy, full-term infants with rigorous monitoring protocols in place 1.
FDA and Guideline Position
The FDA drug label explicitly advises against breastfeeding on lithium except in exceptional circumstances where benefits to the mother clearly outweigh risks to the infant 1. The AAP guideline references LactMed as the primary resource for medication safety during lactation but does not provide lithium-specific guidance 2.
Evidence for Selective Breastfeeding with Monitoring
Recent research challenges the blanket contraindication, showing that:
Lithium transfer and infant exposure: Lithium completely crosses the placenta at delivery (cord-to-maternal ratio ~1.12), but infant serum levels decline significantly during breastfeeding 3, 4. In exclusively breastfed infants, lithium levels decreased 44% by one month and 60% by three months postpartum, with no accumulation observed 3, 4.
Infant outcomes: Among 24 mother-infant pairs across different feeding strategies, no sustained lithium accumulation or developmental delays occurred in breastfed infants 3. A 2024 study of 18 postpartum cases found no adverse events in four monitored breastfed infants (average maternal dose 750 mg daily, maternal level 0.62 mmol/L, infant level 0.16 mmol/L) 5.
Critical Risk Factors and Monitoring
High lithium concentration at delivery (≥0.6 mEq/L) is a significant risk factor 6. In one cohort, 85.7% of high-exposure infants had neonatal symptoms versus 41.2% in low-exposure infants, with 28.6% requiring neonatal intensive care 6. Most symptoms were transient and mild, but two infants maintained therapeutic lithium levels at follow-up 6.
Recommended Approach
If breastfeeding is pursued, implement this monitoring protocol:
Maternal considerations: Reduce lithium dose postpartum if possible while maintaining psychiatric stability; monitor maternal levels closely as renal clearance normalizes after delivery 1
Infant eligibility: Only healthy, full-term infants should be considered; preterm or ill infants are at higher risk
Infant monitoring schedule:
- Baseline infant serum lithium and creatinine at birth
- Repeat at days 1-5,7-11,30, and 60 postpartum
- Monthly monitoring until 6 months if continuing 4
- More frequent monitoring if maternal dose >750 mg daily or infant lithium >0.2 mmol/L
Clinical surveillance: Assess infant for hypotonia, lethargy, poor feeding, temperature instability, and cyanosis at each visit 6, 4
Time to clearance: Formula-fed infants reach undetectable levels in 6-8 days; exclusively breastfed infants require 53-60 days 3
Common Pitfalls
- Polypharmacy: Additional psychotropic medications increase risk of infant symptoms 6
- Dehydration: Both maternal dehydration (increasing lithium levels) and infant dehydration (from poor feeding) can precipitate toxicity 1
- Drug interactions: NSAIDs, diuretics, and ACE inhibitors increase maternal lithium levels and require dose adjustment 1
- Delayed follow-up: Infants with therapeutic lithium levels at birth need prompt reassessment to prevent toxicity 6
Alternative Strategy
Mixed feeding (combination of breast milk and formula) provides a middle ground, achieving infant lithium clearance in 7-8 days while maintaining some breastfeeding benefits 3. This may be preferable for mothers with higher lithium requirements or infants with elevated birth levels.
The systematic review of case reports through 2018 concluded that data remain limited and adverse effects are difficult to separate from gestational exposure and other factors 7. However, the most recent prospective data from 2021-2024 show more favorable outcomes with structured monitoring 5, 3, 4.